Friday 6 November 2026
Export BNTX’s income statement to Excel — free account
BioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
87.01
1.15
+1.34%
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) P/E ratio
BioNTech SE Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 747× (February 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 27.1× | 653.24% |
| FY2022 | 3.6× | (30.77%) |
| FY2021 | 5.2× | (98.98%) |
| FY2020 | 510× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 24 more quarters | Free account |
Against its own ten years
Low 0.0×
High 747×
Ten-year median
0.0×
Current reading's percentile
51
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | n/m |
| BNTX BioNTech SE Sponsored ADR | n/m |
| BBIO BridgeBio Pharma, Inc. compare | n/m |
| INSM Insmed, Inc. compare | n/m |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 7.9× |
| ASND Ascendis Pharma A/S compare | 18.3× |
| EXEL Exelixis, Inc. compare | 19.9× |
| GMAB Genmab A/S Sponsored ADR compare | 41.7× |
| INCY Incyte Corporation compare | 56.3× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement